High materiality8/10
Genmab price target raised to $58 from $54 at Guggenheim
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Guggenheim raises Genmab target to $58. Current price $37.80. Upside potential remains; bullish setup.
- Target raised to $58; price $37.80; bullish setup.
Key facts
- 01
Target: $58
- 02
Posted price: $37.8
- 03
Analyst firm: Guggenheim
- 04
Analyst: Michael Schmidt
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.